The advent of IDH inhibitors is a major milestone in the field of AML targeted therapy, verifying the targeting of the consistent disease axis from gene mutations to metabolic abnormalities and epigenetic regulation. This evidence concerns the gene IDH1 and acute myeloid leukemia.